<DOC>
	<DOCNO>NCT01978860</DOCNO>
	<brief_summary>This prospective , non-randomized , first-in-man investigational study , assess safety technical feasibility , deployment withdrawal characteristic NovaCross™ micro-catheter interventional coronary angioplasty procedure evaluate CTO penetration rate . Each study subject/patient total one ( 1 ) procedure perform study .</brief_summary>
	<brief_title>A Prospective , First Man Study Evaluate Safety Performance NovaCross™ Micro-catheter</brief_title>
	<detailed_description>To fill later</detailed_description>
	<criteria>1 . Adult age 2580 2 . Patient understands sign study inform consent form . 3 . Patient angiographic document Chronic Total Occlusion ( i.e . &gt; 3 month occlusion duration ) show distal TIMI flow 0 . 4 . Suitable candidate nonemergent , coronary angioplasty 5 . Documented coronary angiography precede PCI reveals least one CTO lesion situate noninfarct related coronary artery side branch follow characteristic : 1 . Thrombolysis Myocardial Infarction ( TIMI ) 0 flow least 90 day ; 2 . Satisfactory distal vessel visualization 3 . CTO amenable percutaneous treatment must locate coronary vessel reference diameter least 2 millimeter . 4 . CTO refractory minimum 10 minute conventional guide wire attempt . 6 . Body Mass Index ( BMI ) &lt; 40 7 . Left ventricle ejection fraction &gt; 25 % For purpose trial , CTO define 100 % luminal narrowing without antegrade flow antegrade retrograde fill collateral vessel . 1 . Patient unable give inform consent . 2 . Current participation another study investigational drug device . 3 . Patient know suspected tolerate contrast agent . 4 . Aortoostial CTO location ( Ostial bifurcation origin may consider ) , SVG CTO instent CTOs . 5 . Intolerance aspirin Clopidogrel Prasugrel Ticagrelor medication 6 . Appearance fresh thrombus intraluminal filling defect . 7 . Recent major cerebrovascular event ( history stroke TIA within 1 month ) 8 . Cardiac intervention within 4 week procedure 9 . Renal insufficiency ( serum creatinine &gt; 2.3mg/dl ) 10 . Active gastrointestinal bleeding 11 . Active infection fever may due infection 12 . Life expectancy &lt; 2 year due illnesses 13 . Significant anemia ( hemoglobin &lt; 8.0 mg / dl ) 14 . Severe uncontrolled systemic hypertension ( &gt; 240 mmHg within 1 month procedure ) 15 . Severe electrolyte imbalance 16 . Congestive heart failure [ New York Heart Association ( NYHA ) Class III\IV ] , CSA Class IV . 17 . Unstable angina require emergent percutaneous transluminal coronary angioplasty ( PTCA ) coronary artery bypass graft ( CABG ) 18 . Recent myocardial infarction ( MI ) ( within past two week ) 19 . Uncontrolled diabetes &gt; 2 serum glucose concentration &gt; 350 mg/dl within 7 day . 20 . Participation another investigational protocol 21 . Unwillingness inability comply protocol requirement 22 . Pregnant nursing 23 . Extensive prior dissection coronary guidewire use 24 . Drug abuse alcoholism . 25 . Patients custodial care . 26 . Bleeding diathesis coagulation disorder ; 27 . Kawasaki 's disease vasculitis .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>CABG Coronary artery bypass grafting</keyword>
	<keyword>CTO Chronic Total Occlusion</keyword>
	<keyword>PCI Percutaneous coronary intervention</keyword>
	<keyword>MACE Major adverse cardiovascular event ( )</keyword>
	<keyword>MI Myocardial infarction</keyword>
</DOC>